Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Transdermal peptide and application thereof

A transdermal and skin-based technology, applied in the field of bioengineering, can solve the problems of pain, high cost, unsuitable for home use, etc., and achieve the effect of transdermal absorption

Active Publication Date: 2016-11-09
深圳市百吉因生物科技有限公司
View PDF3 Cites 8 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, the physical method has many shortcomings, including the use of special instruments, high cost, poor flexibility of dosage forms, etc., and it is painful to varying degrees, and is not suitable for home use, etc.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Transdermal peptide and application thereof
  • Transdermal peptide and application thereof
  • Transdermal peptide and application thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0015] Example 1. Polypeptide SEQ ID No 1: ACSSTKKHCG was synthesized by solid phase synthesis.

[0016] Microwave-assisted solid-phase synthesis of peptides was adopted: Wang resin was used as a solid-phase carrier, HBTU-HOBt was used as a condensation agent, and Fmoc was used as a synthetic strategy for the α-amino protecting group. Weigh 0.1 mmol of Fmoc-glycine-Wang resin into a solid-phase reactor, add 10 mL of DCM to swell the resin for 30 min, wait until the resin is fully swollen, and vacuum the solvent to dry up. Wash once with 20% piperidine / DMF10mL, add 20% piperidine / DMF10mL to the resin and place it in a microwave-assisted solid-phase synthesizer, react at 60°C and 20W for 3min to remove the Fmoc protecting group, then use DCM, Washing with DMF, removal of protective group is detected by Kaiser method, if the detection is positive, the reaction can be continued. Dissolve 3eq of Fmoc-amino acid-OH, HBTU and HOBt in DMF, add dropwise 5eq of DIEA and let it stand fo...

Embodiment 2

[0017] Embodiment 2, animal experiments verify transdermal activity

[0018] This example is to study the transdermal effect of the transdermal polypeptide at the mouse level, and the specific steps are as follows.

[0019] 1. Shave the mice 36 hours before the experiment to obtain Hairless skin.

[0020] 2. Bacteria solution (purchased from Beijing Tianenze) was added to 4 mL medium, incubated at 37°C, and centrifuged at 180 rpm for 4h.

[0021] 3. The mice were anesthetized with 3.5% chloral hydrate, the anesthesia dose was .

[0022] 4. After each mouse is prepared skin surface, plus Phage.

[0023] 5. Take blood for half an hour and one hour respectively , mixed and added to 1 mL of the bacterial solution prepared in step 2, incubated at 37°C, and centrifuged at 120 rpm for 40 minutes.

[0024] 6. Use the blue-white screening method for the second step mixture overnight to obtain figure 1 The results shown.

[0025] 7. Pick blue spots, amplify and extrac...

Embodiment 3

[0026] Example 3. Research on Transdermal Peptide Assisted siRNA Transdermal Activity

[0027] This example is to study the transdermal effect of the transdermal polypeptide at the level of rats, and the specific steps are as follows.

[0028] 1. Shave the rats 36 hours before the experiment to get Hairless skin.

[0029] 2. Thoroughly mix a small amount (about 0.1 g) of cosmetic base with 1 mg of chemically synthesized SEQ ID No1 polypeptide and fluorescently labeled siRNA (100 ng).

[0030] 3. Apply the mixture evenly to the skin of rats that have been depilated, and wrap the skin with plastic wrap.

[0031]4. After 1 hour, the rats were sacrificed, the skin was separated, and the skin surface was washed with PBS, and then the skin samples were embedded and frozen into sections under liquid nitrogen quick-freezing conditions. The transdermal effect of siRNA was observed by confocal microscopy. get figure 2 The results shown. From the figure, we can see that the skin ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention provides polypeptide with a transdermal function or a transdermal enhanced function and a nucleotide sequence for encoding the polypeptide. The polypeptide can promote and / or enhance transdermal permeation of other substances, and the substances include micromolecular active substances and macromolecular active substances such as protein and nucleic acid. The invention further provides compositions containing the transdermal peptide, wherein the compositions include a beautifying agent, a hairdressing agent, a drug composition and the like.

Description

technical field [0001] The invention belongs to the field of bioengineering, in particular, the invention relates to a polypeptide with enhanced transdermal function. Background technique [0002] Transdermal Drug Delivery Systems / Transdermal Thrapeutic Systems (TDDS / TTS for short), refers to the way of applying medicine through skin application or smearing, and the medicine is absorbed through the skin into the blood circulation of the whole body and reaches the effective blood concentration , A method to achieve disease treatment or prevention. Its main features: (1) The transdermal drug delivery system can avoid the first-pass effect of the liver and the inactivation of the drug in the gastrointestinal tract, and the absorption of the drug is not affected by the gastrointestinal factors and reduces the individual differences in medication; (2) Maintain a constant effective blood drug concentration or physiological effects, avoid the peak and valley phenomenon of blood dr...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): C07K7/06C12N15/11A61K8/64A61Q19/00A61Q5/00A61K47/42A61K31/7105A61K48/00A61K38/18
Inventor 汤涛杜权邓艳东硕
Owner 深圳市百吉因生物科技有限公司
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com